Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Acta Diabetologica
Erschienen in: Acta Diabetologica 1/2011

01.03.2011 | Review Article

The IGF system

verfasst von: Marta Annunziata, Riccarda Granata, Ezio Ghigo

Erschienen in: Acta Diabetologica | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The insulin-like growth factor (IGF) system plays essential role in the regulation of cell growth, proliferation and survival and affects nearly every organ system in the body. IGF-I, which has a high structural similarity to insulin, exerts growth-promoting effects, influences glucose metabolism and has neuroprotective and cardioprotective effects, partly because of its cell-proliferative and antiapoptotic properties. Aberrations in the IGF system may associate with various pathological conditions, including cancer. Insulin and its synthetic analogs are known to possess IGF-IR binding affinity, and concern has been raised about their mitogenic potential in humans. The present review summarizes the main aspects of the IGF system biology and the interactions among IGF-I, insulin, insulin analogs and their receptors.
Literatur
1.
2.
Federici M, Porzio O, Zucaro L, Fusco A, Borboni P, Lauro D, Sesti G (1997) Distribution of insulin/insulin-like growth factor-i hybrid receptors in human tissues. Mol Cell Endocrinol 129(2):121–126. doi:S0303-7207(97)04050-1[pii] PubMed
3.
Salmon WD Jr, Daughaday WH (1957) A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 49(6):825–836PubMed
4.
Daughaday WH, Hall K, Raben MS, Salmon WD Jr, van den Brande JL, van Wyk JJ (1972) Somatomedin: proposed designation for sulphation factor. Nature 235(5333):107PubMed
5.
Froesch ER, Buergi H, Ramseier EB, Bally P, Labhart A (1963) Antibody-suppressible and nonsuppressible insulin-like activities in human serum and their physiologic significance. An insulin assay with adipose tissue of increased precision and specificity. J Clin Invest 42:1816–1834. doi:10.​1172/​JCI104866 PubMed
6.
Blundell TL, Bedarkar S, Rinderknecht E, Humbel RE (1978) Insulin-like growth factor: a model for tertiary structure accounting for immunoreactivity and receptor binding. Proc Natl Acad Sci USA 75(1):180–184PubMed
7.
Rinderknecht E, Humbel RE (1978) The amino acid sequence of human insulin-like growth factor i and its structural homology with proinsulin. J Biol Chem 253(8):2769–2776PubMed
8.
Klapper DG, Svoboda ME, Van Wyk JJ (1983) Sequence analysis of somatomedin-c: confirmation of identity with insulin-like growth factor i. Endocrinology 112(6):2215–2217PubMed
9.
Daughaday WH, Hall K, Salmon WD Jr, Van den Brande JL, Van Wyk JJ (1987) On the nomenclature of the somatomedins and insulin-like growth factors. J Clin Endocrinol Metab 65(5):1075–1076PubMed
10.
11.
12.
Brissenden JE, Ullrich A, Francke U (1984) Human chromosomal mapping of genes for insulin-like growth factors i and ii and epidermal growth factor. Nature 310(5980):781–784PubMed
13.
Tricoli JV, Rall LB, Scott J, Bell GI, Shows TB (1984) Localization of insulin-like growth factor genes to human chromosomes 11 and 12. Nature 310(5980):784–786PubMed
14.
Rotwein P, Pollock KM, Didier DK, Krivi GG (1986) Organization and sequence of the human insulin-like growth factor i gene. Alternative RNA processing produces two insulin-like growth factor i precursor peptides. J Biol Chem 261(11):4828–4832PubMed
15.
Smith PJ, Spurrell EL, Coakley J, Hinds CJ, Ross RJ, Krainer AR, Chew SL (2002) An exonic splicing enhancer in human igf-i pre-mrna mediates recognition of alternative exon 5 by the serine-arginine protein splicing factor-2/alternative splicing factor. Endocrinology 143(1):146–154PubMed
16.
Sussenbach JS, Steenbergh PH, Holthuizen P (1992) Structure and expression of the human insulin-like growth factor genes. Growth Regul 2(1):1–9PubMed
17.
Li CH, Yamashiro D, Gospodarowicz D, Kaplan SL, Van Vliet G (1983) Total synthesis of insulin-like growth factor i (somatomedin c). Proc Natl Acad Sci USA 80(8):2216–2220PubMed
18.
Blundell TL, Bedarkar S, Humbel RE (1983) Tertiary structures, receptor binding, and antigenicity of insulin like growth factors. Fed Proc 42(9):2592–2597PubMed
19.
20.
Baxter RC, Martin JL (1989) Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog Growth Factor Res 1(1):49–68PubMed
21.
Firth SM, Baxter RC (2002) Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23(6):824–854PubMed
22.
Rapp R, Deger A, Blum W, Koch R, Weber U (1988) Characterization of the protein which binds insulin-like growth factor in human serum. Eur J Biochem 172(2):421–425PubMed
23.
Le Roith D, Bondy C, Yakar S, Liu JL, Butler A (2001) The somatomedin hypothesis: 2001. Endocr Rev 22(1):53–74PubMed
24.
Kim HS, Ingermann AR, Tsubaki J, Twigg SM, Walker GE, Oh Y (2004) Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in mcf-7 human breast cancer cells. Cancer Res 64(6):2229–2237PubMed
25.
Perks CM, Newcomb PV, Norman MR, Holly JM (1999) Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells. J Mol Endocrinol 22(2):141–150PubMed
26.
Granata R, Trovato L, Garbarino G, Taliano M, Ponti R, Sala G, Ghidoni R, Ghigo E (2004) Dual effects of igfbp-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J 18(12):1456–1458. doi:10.​1096/​fj.​04-1618fje04-1618fje[pii] PubMed
27.
28.
29.
Heldin CH, Ostman A (1996) Ligand-induced dimerization of growth factor receptors: variations on the theme. Cytokine Growth Factor Rev 7(1):3–10. doi:1359610196000020​[pii] PubMed
30.
House PD, Weidemann MJ (1970) Characterization of an [125 i]-insulin binding plasma membrane fraction from rat liver. Biochem Biophys Res Commun 41(3):541–548. doi:0006-291X(70)90046-X[pii] PubMed
31.
Freychet P, Roth J, Neville DM Jr (1971) Insulin receptors in the liver: specific binding of (125 i)insulin to the plasma membrane and its relation to insulin bioactivity. Proc Natl Acad Sci USA 68(8):1833–1837PubMed
32.
Cuatrecasas P (1971) Insulin–receptor interactions in adipose tissue cells: direct measurement and properties. Proc Natl Acad Sci USA 68(6):1264–1268PubMed
33.
34.
Yip CC, Yeung CW, Moule ML (1980) Photoaffinity labeling of insulin receptor proteins of liver plasma membrane preparations. Biochemistry 19(1):70–76PubMed
35.
Massague J, Czech MP (1982) The subunit structures of two distinct receptors for insulin-like growth factors i and ii and their relationship to the insulin receptor. J Biol Chem 257(9):5038–5045PubMed
36.
Shia MA, Pilch PF (1983) The beta subunit of the insulin receptor is an insulin-activated protein kinase. Biochemistry 22(4):717–721PubMed
37.
Roth RA, Cassell DJ (1983) Insulin receptor: evidence that it is a protein kinase. Science 219(4582):299–301PubMed
38.
Kasuga M, Fujita-Yamaguchi Y, Blithe DL, Kahn CR (1983) Tyrosine-specific protein kinase activity is associated with the purified insulin receptor. Proc Natl Acad Sci USA 80(8):2137–2141PubMed
39.
Kasuga M, Fujita-Yamaguchi Y, Blithe DL, White MF, Kahn CR (1983) Characterization of the insulin receptor kinase purified from human placental membranes. J Biol Chem 258(18):10973–10980PubMed
40.
Pashmforoush M, Chan SJ, Steiner DF (1996) Structure and expression of the insulin-like peptide receptor from amphioxus. Mol Endocrinol 10(7):857–866PubMed
41.
Megyesi K, Kahn CR, Roth J, Neville DM Jr, Nissley SP, Humbel RE, Froesch ER (1975) The nsila-s receptor in liver plasma membranes. Characterization and comparison with the insulin receptor. J Biol Chem 250(23):8990–8996PubMed
42.
Marshall RN, Underwood LE, Voina SJ, Foushee DB, Van Wyk JJ (1974) Characterization of the insulin and somatomedin-c receptors in human placental cell membranes. J Clin Endocrinol Metab 39(2):283–292PubMed
43.
Bhaumick B, Bala RM, Hollenberg MD (1981) Somatomedin receptor of human placenta: solubilization, photolabeling, partial purification, and comparison with insulin receptor. Proc Natl Acad Sci USA 78(7):4279–4283PubMed
44.
Chernausek SD, Jacobs S, Van Wyk JJ (1981) Structural similarities between human receptors for somatomedin c and insulin: analysis by affinity labeling. Biochemistry 20(26):7345–7350PubMed
45.
Jacobs S, Kull FC Jr, Earp HS, Svoboda ME, Van Wyk JJ, Cuatrecasas P (1983) Somatomedin-c stimulates the phosphorylation of the beta-subunit of its own receptor. J Biol Chem 258(16):9581–9584PubMed
46.
Rubin JB, Shia MA, Pilch PF (1983) Stimulation of tyrosine-specific phosphorylation in vitro by insulin-like growth factor i. Nature 305(5933):438–440PubMed
47.
Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E et al (1986) Insulin-like growth factor i receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5(10):2503–2512PubMed
48.
Jacobs S, Kull FC Jr, Cuatrecasas P (1983) Monensin blocks the maturation of receptors for insulin and somatomedin c: identification of receptor precursors. Proc Natl Acad Sci USA 80(5):1228–1231PubMed
49.
Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, Rutter WJ, Roth RA (1988) Expression and characterization of a functional human insulin-like growth factor i receptor. J Biol Chem 263(23):11486–11492PubMed
50.
Sasaki N, Rees-Jones RW, Zick Y, Nissley SP, Rechler MM (1985) Characterization of insulin-like growth factor i-stimulated tyrosine kinase activity associated with the beta-subunit of type i insulin-like growth factor receptors of rat liver cells. J Biol Chem 260(17):9793–9804PubMed
51.
Soos MA, Siddle K (1989) Immunological relationships between receptors for insulin and insulin-like growth factor i. Evidence for structural heterogeneity of insulin-like growth factor i receptors involving hybrids with insulin receptors. Biochem J 263(2):553–563PubMed
52.
Soos MA, Field CE, Siddle K (1993) Purified hybrid insulin/insulin-like growth factor-i receptors bind insulin-like growth factor-i, but not insulin, with high affinity. Biochem J 290(Pt 2):419–426PubMed
53.
54.
Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks JR, Iglehart JD, Jirtle RL (1996) M6p/igf2 receptor: a candidate breast tumor suppressor gene. Oncogene 12(9):2003–2009PubMed
55.
O’Gorman DB, Weiss J, Hettiaratchi A, Firth SM, Scott CD (2002) Insulin-like growth factor-ii/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology 143(11):4287–4294PubMed
56.
57.
Shier P, Watt VM (1989) Primary structure of a putative receptor for a ligand of the insulin family. J Biol Chem 264(25):14605–14608PubMed
58.
Zhang B, Roth RA (1992) The insulin receptor-related receptor. Tissue expression, ligand binding specificity, and signaling capabilities. J Biol Chem 267(26):18320–18328PubMed
59.
Nakae J, Kido Y, Accili D (2001) Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 22(6):818–835PubMed
60.
61.
Hadsell DL (2004) Genetic manipulation of mammary gland development and lactation. Adv Exp Med Biol 554:229–251PubMed
62.
63.
Humbert S, Bryson EA, Cordelieres FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F (2002) The igf-1/akt pathway is neuroprotective in Huntington’s disease and involves Huntingtin phosphorylation by akt. Dev Cell 2(6):831–837. doi:S153458070200188​0[pii] PubMed
64.
Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I (2002) Serum insulin-like growth factor i regulates brain amyloid-beta levels. Nat Med 8(12):1390–1397. doi:10.​1038/​nm793nm793[pii] PubMed
65.
Aleman A, Verhaar HJ, De Haan EH, De Vries WR, Samson MM, Drent ML, Van der Veen EA, Koppeschaar HP (1999) Insulin-like growth factor-i and cognitive function in healthy older men. J Clin Endocrinol Metab 84(2):471–475PubMed
66.
67.
Li B, Setoguchi M, Wang X, Andreoli AM, Leri A, Malhotra A, Kajstura J, Anversa P (1999) Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ Res 84(9):1007–1019PubMed
68.
Welch S, Plank D, Witt S, Glascock B, Schaefer E, Chimenti S, Andreoli AM, Limana F, Leri A, Kajstura J, Anversa P, Sussman MA (2002) Cardiac-specific igf-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res 90(6):641–648PubMed
69.
70.
71.
72.
73.
74.
Sara VR, Hall K (1990) Insulin-like growth factors and their binding proteins. Physiol Rev 70(3):591–614PubMed
75.
Pardee AB (1989) G1 events and regulation of cell proliferation. Science 246(4930):603–608PubMed
76.
77.
Werner H, Karnieli E, Rauscher FJ, LeRoith D (1996) Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor i receptor gene. Proc Natl Acad Sci USA 93(16):8318–8323PubMed
78.
79.
80.
81.
Camacho-Hubner C, Woods KA, Clark AJ, Savage MO (2002) Insulin-like growth factor (igf)-i gene deletion. Rev Endocr Metab Disord 3(4):357–361PubMed
82.
Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J (2000) The combination of insulin-like growth factor i and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 85(4):1518–1524PubMed
83.
84.
Cusi K, DeFronzo R (2000) Recombinant human insulin-like growth factor i treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 85(9):3077–3084PubMed
85.
Saukkonen T, Shojaee-Moradie F, Williams RM, Amin R, Yuen KC, Watts A, Acerini CL, Umpleby AM, Dunger DB (2006) Effects of recombinant human igf-i/igf-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes 55(8):2365–2370. doi:55/​8/​2365[pii]10.​2337/​db05-1646 PubMed
86.
Henry RR, Abrams L, Nikoulina S, Ciaraldi TP (1995) Insulin action and glucose metabolism in nondiabetic control and niddm subjects. Comparison using human skeletal muscle cell cultures. Diabetes 44(8):936–946PubMed
87.
Baudry A, Lamothe B, Bucchini D, Jami J, Montarras D, Pinset C, Joshi RL (2001) Igf-1 receptor as an alternative receptor for metabolic signaling in insulin receptor-deficient muscle cells. FEBS Lett 488(3):174–178. doi:S0014-5793(00)02435-2[pii] PubMed
88.
89.
90.
DeChiara TM, Efstratiadis A, Robertson EJ (1990) A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor ii gene disrupted by targeting. Nature 345(6270):78–80. doi:10.​1038/​345078a0 PubMed
91.
Giannoukakis N, Deal C, Paquette J, Goodyer CG, Polychronakos C (1993) Parental genomic imprinting of the human igf2 gene. Nat Genet 4(1):98–101. doi:10.​1038/​ng0593-98 PubMed
92.
93.
Reeve AE, Eccles MR, Wilkins RJ, Bell GI, Millow LJ (1985) Expression of insulin-like growth factor-ii transcripts in wilms’ tumour. Nature 317(6034):258–260PubMed
94.
Lammers R, Gray A, Schlessinger J, Ullrich A (1989) Differential signalling potential of insulin- and igf-1-receptor cytoplasmic domains. EMBO J 8(5):1369–1375PubMed
95.
Shymko RM, Dumont E, De Meyts P, Dumont JE (1999) Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding. Biochem J 339(Pt 3):675–683PubMed
96.
97.
Mynarcik DC, Williams PF, Schaffer L, Yu GQ, Whittaker J (1997) Identification of common ligand binding determinants of the insulin and insulin-like growth factor 1 receptors. Insights into mechanisms of ligand binding. J Biol Chem 272(30):18650–18655PubMed
98.
Zelobowska K, Gumprecht J, Grzeszczak W (2009) Mitogenic potency of insulin glargine. Endokrynol Pol 60(1):34–39PubMed
99.
Schwartz GP, Burke GT, Katsoyannis PG (1987) A superactive insulin: [b10-aspartic acid]insulin(human). Proc Natl Acad Sci USA 84(18):6408–6411PubMed
100.
Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ (1991) Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 34(5):307–313PubMed
101.
Drejer K (1992) The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8(3):259–285PubMed
102.
103.
Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, Klein HH, Lundemose AG (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315(Pt 1):271–279PubMed
104.
105.
Bahr M, Kolter T, Seipke G, Eckel J (1997) Growth promoting and metabolic activity of the human insulin analogue [glya21, argb31, argb32]insulin (hoe 901) in muscle cells. Eur J Pharmacol 320(2–3):259–265. doi:S0014-2999(96)00903-X[pii] PubMed
106.
107.
Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR (2001) Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and igf-i. J Clin Endocrinol Metab 86(12):5838–5847PubMed
108.
Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49(6):999–1005PubMed
109.
Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16(2):429–441. doi:ERC-08-0240[pii]10.​1677/​ERC-08-0240 PubMed
110.
Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2009) Insulin analogues display igf-i-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25(1):41–49. doi:10.​1002/​dmrr.​912 PubMed
111.
Mayer D, Chantelau E (2010) Treatment with insulin glargine (lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on mcf-7 breast cancer cells. Arch Physiol Biochem 116(2):73–78. doi:10.​3109/​1381345100363143​9 PubMed
112.
Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU (1998) The long acting human insulin analog hoe 901: characteristics of insulin signalling in comparison to asp(b10) and regular insulin. Horm Metab Res 30(3):123–129. doi:10.​1055/​s-2007-978849 PubMed
113.
Staiger K, Staiger H, Schweitzer MA, Metzinger E, Balletshofer B, Haring HU, Kellerer M (2005) Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 48(9):1898–1905. doi:10.​1007/​s00125-005-1874-4 PubMed
114.
Erbel S, Reers C, Eckstein VW, Kleeff J, Buchler MW, Nawroth PP, Ritzel RA (2008) Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 31(6):1105–1111. doi:dc07-2015[pii]10.​2337/​dc07-2015 PubMed
115.
Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M (2007) Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 39(1):65–67. doi:10.​1055/​s-2007-957352 PubMed
116.
Liefvendahl E, Arnqvist HJ (2008) Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and igf-i. Horm Metab Res 40(6):369–374. doi:10.​1055/​s-2008-1062739 PubMed
117.
Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G (2002) Evaluation of the carcinogenic potential of insulin glargine (lantus) in rats and mice. Int J Toxicol 21(3):171–179. doi:10.​1080/​1091581029009630​6 PubMed
118.
Eckardt K, May C, Koenen M, Eckel J (2007) Igf-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50(12):2534–2543. doi:10.​1007/​s00125-007-0815-9 PubMed
Metadaten
Titel
The IGF system
verfasst von
Marta Annunziata
Riccarda Granata
Ezio Ghigo
Publikationsdatum
01.03.2011
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 1/2011
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-010-0227-z

Weitere Artikel der Ausgabe 1/2011

Acta Diabetologica 1/2011 Zur Ausgabe

Original Article

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas

Original Article

Study of coronary artery calcification risk in Egyptian adolescents with type-1 diabetes

Original Article

The severity of coronary atherosclerosis in diabetic and non-diabetic metabolic syndrome patients diagnosed according to different criteria and undergoing elective angiography

Original Article

The dual-wave bolus feature in type 1 diabetes adult users of insulin pumps

Original Article

The relationship between uric acid and metabolic syndrome in normal glucose tolerance and normal fasting glucose subjects

Original Article

Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise